Inactive Instrument

News XenoPort, Inc.

Equities

US98411C1009

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

XenoPort : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort	16-07-05	BU
XenoPort : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period	16-06-16	BU
Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. and Encourages Investors to Contact the Firm for Additional Information	16-05-24	BU
Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT	16-05-24	PR
Ryan & Maniskas, LLP : Announces Investigation of XenoPort, Inc.	16-05-24	PR
XENOPORT, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Arbor Pharmaceuticals, LLC May Be Unfair to Shareholders	16-05-23	BU
XenoPort : Arbor Pharmaceuticals to Acquire XenoPort	16-05-23	BU
XenoPort : Reports First Quarter Financial Results	16-05-05	BU
XenoPort : to Release First Quarter Financial Results on May 5, 2016	16-04-26	BU
XenoPort : Dr. Reddy's Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829	16-03-28	PU
XenoPort : #StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness Week 2016	16-03-07	BU
XenoPort : to Present at the Cowen and Company 36th Annual Health Care Conference	16-03-01	BU
XenoPort : Reports Fourth Quarter and Year-End 2015 Financial Results	16-02-25	BU
XenoPort : to Release Fourth Quarter and Year-End Financial Results on February 25, 2016	16-02-16	BU
XenoPort : Reports Third Quarter Financial Results	15-11-04	BU
XenoPort : to Present at the Credit Suisse Healthcare Conference	15-10-29	BU
XenoPort : to Release Third Quarter Financial Results on November 4	15-10-27	BU
XenoPort : Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director	15-10-01	BU
XenoPort : Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis	15-09-15	BU
XenoPort : to Present at the Morgan Stanley Global Healthcare Conference	15-09-04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News XenoPort, Inc.

Equities

US98411C1009

Summary

Filters